Bluejay Diagnostics Releases Q3 2026 Financial Report and Business Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced its financial results for Q3 2026, alongside updates on clinical and manufacturing progress. The company focuses on rapid diagnostic solutions for critical care. During the third quarter, Bluejay hit significant milestones, such as completing the SYMON-II clinical study enrollment and establishing an alternative manufacturing site before schedule.

Clinically, Bluejay surpassed its SYMON-II enrollment target, analyzing data from 777 patients, including 140 deaths within 28 days. The company progresses toward an FDA 510(k) submission for its Symphony IL-6 test, projected for the first half of 2027, pending successful validation.

Manufacturing capabilities were boosted with a new facility and agreements to strengthen commercial infrastructure, including a distribution deal with Lovell Government Services. Financially, Bluejay had $7.38 million in cash as of September 30, anticipating the need for additional funds beyond Q2 2027 for continued operations and development.